ME02239B - Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta - Google Patents
Humana antitela visokog afiniteta prema humanom nervnom faktoru rastaInfo
- Publication number
- ME02239B ME02239B MEP-2014-642A MEP64214A ME02239B ME 02239 B ME02239 B ME 02239B ME P64214 A MEP64214 A ME P64214A ME 02239 B ME02239 B ME 02239B
- Authority
- ME
- Montenegro
- Prior art keywords
- antibody
- pain
- antigen
- binding fragment
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Humano antitelo ili antigen-vezujući fragment antitela, koji specifično vezuje humani nervni faktor rasta (NGF) sa KD od 1 pM ili manje, kako je izmereno uz pomoć površinske plazmon rezonance, pri čemu antitelo ili fragment antitela sadrži (a) region koji određuje komplementarnost teškog lanca 3 (HCDR3) i CDR3 lakog lanca (LCDR3), pri čemu HCDR3 i LCDR3 sadrže aminikiselinske sekvence navedene u SEQ ID NO:90, odnosno 98, i (b) HCDR1, HCDR2, LCDR1 i LCDR2, pri čemu: HCDR1 je SEQ ID NO:86, HCDR2 je SEQ ID NO:88, LCDR1 je SEQ ID NO:94 i LCDR2 je SEQ ID NO:96.
2. Humano antitelo ili antigen-vezujući fragment prema zahtevu 1, koji specifično vezuje humani NGF sa Kd od 0.5 pM ili manje.
3. Humano antitelo ili antigen-vezujući fragment prema zahtevu 1 ili 2, pri čemu navedeno antitelo ili njegov antigen-vezujući fragment sadrži varijabilni region teškog lanca (HCVR) i varijabilni region lakog lanca (LCVR), pri čemu HCVR i LCVR sadrže aminokiselinske sekvence navedene u SEQ ID NO:108, odnosno 110.
4. Humano antitelo ili antigen-vezujući fragment prema zahtevu 1, 2 ili 3, koji vezuje humani NGF sa Kd koja je približno 2 do približno 10-puta veća nego kada antitelo ili fragment vezuje NGF pacova i miša.
5. Molekul nukleinske kiseline, koji kodira humano antitelo ili antigen-vezujući fragment prema bilo kom od zahteva 1 do 4.
6. Ekspresioni vektor koji sadrži nukleinsku kiselinu iz zahteva 5.
7. Postupak proizvodnje antitela prema humanom NGF-u ili antigen-vezujućeg fragmenta antitela koji obuhvata korake uvođenja ekspresionog vektora iz zahteva 6 u izolovanu ćeliju domaćina, uzgoj ćelije pod uslovima koji omogućuju proizvodnju antitela ili fragmenta antitela, i dobijanje tako proizvedenog antitela ili fragmenta antitela, pri čemu je poželjno ćelija domaćina ćelija E. coli, CHO ćelija ili COS ćelija.
8. Farmaceutska smeša koja sadrži antitelo ili antigen-vezujući fragment antitela prema bilo kom od zahteva 1 do 4 i farmaceutski prihvatljiv nosač.
9. Farmaceutska smeša prema zahtevu 8 koja dalje sadrži drugo terapeutsko sredstvo odabrano od: inhibitora interleukina-1 (IL-1), antiepileptičnog leka, antagonista citokina i neurotrofina.
10. Antitelo ili antigen-vezujući fragment antitetla prema bilo kom od zahteva 1 do 4 za korišćenje u postupku ublažavanja ili inhibiranja NGF-om posredovane bolesti ili stanja kod čoveka, koje su odabrane od: inflamatornog bola, post-operativnog incizionog bola, neuropatskog bola, bola zbog preloma, bola zbog zglobnog gihta, post-herpesne neuralgije, bola proisteklog od opekotina, kancerskog bola, bola osteoartritisa ili reumatoidnog artritisa, išijasnog bola, bola povezanog sa krizama bolesti srpastih ćelija ili post-herpesne neuralgije.
11. Korišćenje antitela ili antigen-vezujućeg fragmenta antitela prema bilo kom od zahteva 1 do 4 u proizvodnji leka za korišćenje u postupku ublažavanja ili inhibiranja NGF-om posredovane bolesti ili stanja kod čoveka, koje su odabrane od: inflamatornog bola, post-operativnog incizionog bola, neuropatskog bola, bola zbog preloma, bola zbog zglobnog gihta, post-herpesne neuralgije, bola proisteklog od opekotina, kancerskog bola, bola osteoartritisa ili reumatoidnog artritisa, išijasnog bola, bola povezanog sa krizama bolesti srpastih ćelija ili post-herpesne neuralgije.
12. Antitelo ili antigen-vezujući fragment antitela prema bilo kom od zahteva 1 do 4 za korišćenje prema zahtevu 10, pri čemu navedeni postupak obuhvata primenu prvog i drugog terapeutskog sredstva humanom ispitaniku kome je to potrebno, pri čemu je prvo terapeutsko sredstvo navedeno antitelo ili antigen-vezujući fragment, i pri čemu je poželjno drugo terapeutsko sredstvo: inhibitor interleukina-1 (IL-1), antiepileptični lek, antagonist citokina ili neurotrofin.
13. Korišćenje prema zahtevu 11 navedenog antitela ili antigen-vezujućeg fragmenta iz bilo kog od zahteva 1 do 4, pri čemu navedeni postupak obuhvata primenu prvog i drugog terapeutskog sredstva humanom ispitaniku kome je to potrebno, pri čemu je prvo terapeutsko sredstvo navedeno antitelo ili antigen-vezujući fragment, i pri čemu je poželjno drugo terapeutsko sredstvo: inhibitor interleukina-1 (IL-1), antiepileptični lek, antagonist citokina ili neurotrofin.
14. Antitelo ili antigen vezujući fragment iz bilo kog od zahteva 1 do 4 za korišćenje prema zahtevu 10 ili 12, pri čemu su stanje ili bolest, koji su posredovani NGF-om, inhibirani bez značajnog narušavanja motorne koordinacije.
15. Korišćenje prema zahtevu 11 ili 13 navedenog antitela ili antigen vezujućeg fragmenta iz bilo kog od zahteva 1 do 4, pri čemu su stanje ili bolest, posredovani NGF-om, inhibirani bez značajnog narušavanja motorne koordinacije.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96422407P | 2007-08-10 | 2007-08-10 | |
| US99452607P | 2007-09-20 | 2007-09-20 | |
| US6286008P | 2008-01-28 | 2008-01-28 | |
| US7925908P | 2008-07-09 | 2008-07-09 | |
| PCT/US2008/072561 WO2009023540A1 (en) | 2007-08-10 | 2008-08-08 | High affinity human antibodies to human nerve growth factor |
| EP08782673.1A EP2187964B1 (en) | 2007-08-10 | 2008-08-08 | High affinity human antibodies to human nerve growth factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02239B true ME02239B (me) | 2015-04-30 |
Family
ID=39951432
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2014-642A ME02239B (me) | 2007-08-10 | 2008-08-08 | Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta |
| MEP-2010-24A ME00977B (me) | 2007-08-10 | 2008-08-08 | Humana antitijela visokog afiniteta prema humanom nervnom faktoru rasta |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2010-24A ME00977B (me) | 2007-08-10 | 2008-08-08 | Humana antitijela visokog afiniteta prema humanom nervnom faktoru rasta |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US7988967B2 (me) |
| EP (2) | EP2572729A3 (me) |
| JP (1) | JP5632744B2 (me) |
| KR (2) | KR101709488B1 (me) |
| CN (1) | CN101827609B (me) |
| AU (1) | AU2008287037B2 (me) |
| BR (1) | BRPI0815370B8 (me) |
| CA (1) | CA2695997C (me) |
| CO (1) | CO6261383A2 (me) |
| CR (1) | CR11298A (me) |
| CY (1) | CY1116072T1 (me) |
| DK (1) | DK2187964T3 (me) |
| DO (1) | DOP2010000054A (me) |
| EC (1) | ECSP10010029A (me) |
| ES (1) | ES2517872T3 (me) |
| HR (1) | HRP20141025T1 (me) |
| IL (1) | IL203558A (me) |
| MA (1) | MA31695B1 (me) |
| ME (2) | ME02239B (me) |
| MX (1) | MX2010001395A (me) |
| MY (2) | MY153781A (me) |
| NI (1) | NI201000021A (me) |
| NZ (1) | NZ583200A (me) |
| PL (1) | PL2187964T3 (me) |
| PT (1) | PT2187964E (me) |
| RS (1) | RS53661B1 (me) |
| RU (1) | RU2473564C2 (me) |
| SI (1) | SI2187964T1 (me) |
| TN (1) | TN2010000059A1 (me) |
| WO (1) | WO2009023540A1 (me) |
| ZA (1) | ZA201000725B (me) |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US9498530B2 (en) * | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| CN102746399B (zh) | 2002-12-24 | 2016-03-02 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| KR101709488B1 (ko) | 2007-08-10 | 2017-02-24 | 리제너론 파아마슈티컬스, 인크. | 인간 신경성장인자에 대한 고친화성 인간 항체 |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
| TR201802935T4 (tr) | 2008-09-19 | 2018-03-21 | Pfizer | Stabil sıvı antikor formülasyonu. |
| DK2350075T3 (da) | 2008-09-22 | 2014-05-26 | Array Biopharma Inc | Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer |
| PT3106463T (pt) | 2008-10-22 | 2018-05-18 | Array Biopharma Inc | Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk |
| AU2016202118B2 (en) * | 2009-03-20 | 2017-10-26 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| CN102459337B (zh) | 2009-05-04 | 2015-05-20 | 雅培研究有限责任公司 | 具有增强的体内稳定性的抗神经生长因子(ngf)抗体 |
| WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| CN102638971B (zh) | 2009-07-08 | 2015-10-07 | 科马布有限公司 | 动物模型及治疗分子 |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| CA2774032C (en) * | 2009-10-23 | 2019-03-26 | Millennium Pharmaceuticals, Inc. | Anti-gcc antibody molecules and related compositions and methods |
| US20110256135A1 (en) | 2010-03-17 | 2011-10-20 | Wolfgang Fraunhofer | Anti-nerve growth factor (ngf) antibody compositions |
| RU2735545C2 (ru) | 2010-05-20 | 2020-11-03 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
| JOP20190250A1 (ar) * | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
| JP6121903B2 (ja) | 2010-08-19 | 2017-04-26 | ゾエティス・ベルジャム・エス・アー | 抗ｎｇｆ抗体およびその使用 |
| AU2015258217A1 (en) * | 2010-08-19 | 2015-12-03 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| KR20190112175A (ko) | 2010-12-01 | 2019-10-02 | 앨더바이오 홀딩스 엘엘씨 | 항―ｎｇｆ 조성물 및 그의 용도 |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| CN102198272B (zh) * | 2011-05-27 | 2013-01-02 | 北京中科拜克生物技术有限公司 | 一种促进骨折愈合的药物组合物 |
| PT2743348T (pt) | 2011-08-11 | 2018-02-23 | Astellas Pharma Inc | Novo anticorpo anti-ngf humano |
| BR112014006390A2 (pt) | 2011-09-19 | 2017-03-28 | Kymab Ltd | anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| EA034689B1 (ru) | 2012-04-27 | 2020-03-06 | Милленниум Фармасьютикалз, Инк. | Молекула антитела к gcc и ее применение для тестирования на чувствительность к gcc-нацеленной терапии |
| JO3820B1 (ar) * | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
| BR112015003032B1 (pt) | 2012-08-13 | 2023-03-28 | Genentech, Inc | Anticorpos isolados, imunoconjugado, formulação farmacêutica e uso do anticorpo |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
| JP6135161B2 (ja) * | 2013-02-08 | 2017-05-31 | アステラス製薬株式会社 | 新規抗ヒトｎｇｆ抗体 |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| CA2922113C (en) | 2013-08-23 | 2023-05-23 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| ES2993142T3 (en) | 2013-10-01 | 2024-12-23 | Kymab Ltd | Animal models and therapeutic molecules |
| JP6556758B2 (ja) * | 2014-01-24 | 2019-08-07 | チャーチ、ウィリアム、アール． | 黄色ブドウ球菌特異的抗体、それを用いた治療方法及び検出方法 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| EP3218380B1 (en) | 2014-11-16 | 2021-03-17 | Array Biopharma, Inc. | Preparation of a crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| AU2015350075B2 (en) | 2014-11-17 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using CD3xCD20 bispecific antibody |
| US11867696B2 (en) | 2015-02-06 | 2024-01-09 | Cell Idx, Inc. | Antigen-coupled immunoreagents |
| CN104910274B (zh) * | 2015-02-12 | 2018-05-04 | 北京华安科创生物技术有限公司 | 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株 |
| CN104777311B (zh) * | 2015-02-12 | 2016-08-17 | 北京华安科创生物技术有限公司 | 抗人神经生长因子hNGF的单克隆抗体及hNGF的定量检测试剂盒 |
| CN104774265B (zh) * | 2015-02-12 | 2018-05-04 | 北京华安科创生物技术有限公司 | 抗人神经生长因子的中和性单克隆抗体11f1及其杂交瘤细胞株 |
| AU2016268625B2 (en) | 2015-05-22 | 2022-01-27 | Astellas Pharma Inc. | Novel anti-human NGF antibody Fab fragment |
| US20180236032A1 (en) * | 2015-08-13 | 2018-08-23 | Merck Patent Gmbh | Combination composition comprising fgf-18 compound |
| TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| IL304018A (en) | 2016-04-04 | 2023-08-01 | Loxo Oncology Inc | Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| CN112409471B (zh) * | 2016-04-13 | 2022-07-29 | 舒泰神（北京）生物制药股份有限公司 | 低痛神经生长因子突变体 |
| ES2952056T3 (es) | 2016-05-18 | 2023-10-26 | Loxo Oncology Inc | Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| US12123874B2 (en) * | 2016-07-18 | 2024-10-22 | Cell Idx, Inc. | Reagent compounds, compositions, kits, and methods for amplified assays |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| AU2017366870B2 (en) * | 2016-11-29 | 2024-09-19 | Regeneron Pharmaceuticals, Inc. | A pharmaceutical composition for averting opioid addiction |
| EP3558347B1 (en) | 2016-12-22 | 2026-01-21 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN114751982B (zh) * | 2017-12-15 | 2023-06-23 | 安源医药科技（上海）有限公司 | 抗人ngf抗体及其制备方法和用途 |
| CN108059676B (zh) * | 2017-12-28 | 2020-07-31 | 未名生物医药有限公司 | 一种抗人神经生长因子scFv抗体及制备方法 |
| CA3093772C (en) | 2018-03-12 | 2024-04-16 | Zoetis Services Llc | Anti-ngf antibodies and methods thereof |
| WO2019200326A1 (en) | 2018-04-13 | 2019-10-17 | Rarecyte, Inc. | Kits for labeling of biomarkers and methods of using the same |
| CN108623687A (zh) * | 2018-04-17 | 2018-10-09 | 中山康方生物医药有限公司 | 神经生长因子的单克隆抗体及其编码基因和应用 |
| EP3795176A4 (en) | 2018-05-15 | 2022-01-12 | Astellas Pharma Inc. | Pharmaceutical composition for suppressing atrial fibrillation having as active ingredient anti-human ngf antibody or antigen-binding fragment thereof |
| US12036242B2 (en) | 2018-07-05 | 2024-07-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CAR T cells that target B-cell antigens |
| EP3833687A1 (en) | 2018-08-10 | 2021-06-16 | Regeneron Pharmaceuticals, Inc. | A pharmaceutical composition for safe and effective treatment of knee and/or hip pain |
| IL280875B2 (en) | 2018-08-31 | 2024-12-01 | Regeneron Pharma | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| JP2020117502A (ja) | 2019-01-28 | 2020-08-06 | ファイザー・インク | 変形性関節症の徴候および症状を処置する方法 |
| EP3927430A1 (en) | 2019-02-18 | 2021-12-29 | Pfizer Inc. | Method of treatment of chronic low back pain |
| EP3947464A4 (en) * | 2019-04-05 | 2023-01-11 | B-Portal Biologics, Inc. | ELASTIC CONSTRUCTIONS AND THEIR USES |
| US11345744B2 (en) | 2019-05-07 | 2022-05-31 | William R Church | Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same |
| CN113924315B (zh) * | 2019-06-10 | 2022-06-28 | 山东博安生物技术股份有限公司 | 抗β-NGF纳米抗体及其应用 |
| WO2021136841A2 (fr) * | 2019-12-31 | 2021-07-08 | Peptinov | Composition pharmaceutique pour la prevention ou le traitement des douleurs post-operatoires |
| CN113527482B (zh) * | 2020-04-17 | 2023-07-21 | 珠海泰诺麦博制药股份有限公司 | 抗人神经生长因子的抗体 |
| CN113527483B (zh) * | 2020-04-17 | 2023-09-22 | 珠海泰诺麦博制药股份有限公司 | 抗人神经生长因子的抗体 |
| EP4157881A4 (en) * | 2020-05-27 | 2024-10-09 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | ANTIBODIES THAT SPECIFICALLY RECOGNIZE NERVE GROWTH FACTOR AND THEIR USES |
| AU2020204105B2 (en) * | 2020-06-19 | 2023-06-08 | Dartsbio Pharmaceuticals Ltd. | Anti-human ngf antibodies and methods using same |
| US11655292B2 (en) | 2020-06-23 | 2023-05-23 | Ampsource Biopharma Shanghai Inc. | Anti-human NGF antibodies and methods using same |
| CN116003590A (zh) * | 2020-08-06 | 2023-04-25 | 熙源安健医药（上海）有限公司 | 抗ngf抗体及其抗原结合片段、其制备方法和应用 |
| EP4217388A1 (en) | 2020-09-28 | 2023-08-02 | MedImmune Limited | Compounds and methods for treating pain |
| CN114470189B (zh) * | 2020-11-12 | 2024-01-16 | 达石药业(广东)有限公司 | Ngf抗体在cipn性疼痛中的应用 |
| US20240117072A1 (en) * | 2020-12-18 | 2024-04-11 | Bioardis, Llc | Fap binding molecules and uses thereof |
| WO2022195504A1 (en) | 2021-03-19 | 2022-09-22 | Pfizer Inc. | Method of treating osteoarthritis pain with an anti ngf antibody |
| CN115725684A (zh) * | 2021-08-28 | 2023-03-03 | 达石药业(广东)有限公司 | 一种Anti-NGF药物细胞增殖抑制活性检定方法 |
| EP4433500A1 (en) | 2021-11-19 | 2024-09-25 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for reducing centralized pain |
| US20250340626A1 (en) | 2021-12-16 | 2025-11-06 | Intervet Inc. | Caninized antibodies to human ngf |
| CN114397453B (zh) * | 2022-03-25 | 2022-06-07 | 江苏美克医学技术有限公司 | 新型冠状病毒突变株的检测试剂盒及其应用 |
| US20240002491A1 (en) | 2022-04-27 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Methods for selecting patients for treatment with an ngf antagonist |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US514294A (en) * | 1894-02-06 | Governor | ||
| US5147294A (en) | 1990-10-01 | 1992-09-15 | Trustees Of Boston University | Therapeutic method for reducing chronic pain in a living subject |
| ES2157903T3 (es) * | 1991-07-10 | 2001-09-01 | Regeneron Pharma | Metodos de tratamiento de trastornos de neuronas motoras utilizando miembros de la familia de moleculas bdnf/nt-3/ngf. |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
| US6548062B2 (en) | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| WO2005056601A2 (en) * | 2003-12-05 | 2005-06-23 | Schreiber John R | Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse? |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AUPR256601A0 (en) * | 2001-01-17 | 2001-02-08 | Silverbrook Research Pty. Ltd. | An apparatus (AP29) |
| CA2975521A1 (en) * | 2001-05-30 | 2002-12-05 | Genentech, Inc. | Anti-ngf antibodies for the treatment of various disorders |
| CA2496419A1 (en) * | 2002-08-19 | 2004-02-26 | Abgenix, Inc. | Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| US7255860B2 (en) | 2002-10-08 | 2007-08-14 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody |
| US7252822B2 (en) | 2002-10-08 | 2007-08-07 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| CN102746399B (zh) * | 2002-12-24 | 2016-03-02 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
| BRPI0407375A (pt) | 2003-02-19 | 2006-02-07 | Rinat Neuroscience Corp | Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos |
| CN1849138B (zh) * | 2003-07-15 | 2011-11-30 | 安姆根有限公司 | 作为选择性ngf途径抑制剂的人抗ngf中和抗体 |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| PL1732949T3 (pl) | 2004-04-07 | 2010-06-30 | Rinat Neuroscience Corp | Sposoby leczenia nowotworowego bólu kości przez podawanie antagonisty czynnika wzrostu nerwów |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| EP1846451B1 (en) * | 2005-01-24 | 2013-05-15 | Medimmune Limited | Human antibodies against human ngf |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| AU2006283194B9 (en) * | 2005-08-25 | 2011-02-03 | Eli Lilly And Company | Anti-IL-23 Antibodies |
| US9789161B2 (en) | 2006-04-28 | 2017-10-17 | Warsaw Orthopedic, Inc. | Methods for treating back or neck pain caused by NGF using a therapeutic agent consisting of ReN-1820, ALE-0540 and capsaicin |
| RS52176B (sr) | 2006-06-02 | 2012-08-31 | Regeneron Pharmaceuticals Inc. | Antitela visokog afiniteta prema humanom il-6 receptoru |
| KR101709488B1 (ko) | 2007-08-10 | 2017-02-24 | 리제너론 파아마슈티컬스, 인크. | 인간 신경성장인자에 대한 고친화성 인간 항체 |
| CN102459337B (zh) | 2009-05-04 | 2015-05-20 | 雅培研究有限责任公司 | 具有增强的体内稳定性的抗神经生长因子(ngf)抗体 |
-
2008
- 2008-08-08 KR KR1020107005181A patent/KR101709488B1/ko active Active
- 2008-08-08 US US12/188,330 patent/US7988967B2/en active Active
- 2008-08-08 CA CA2695997A patent/CA2695997C/en active Active
- 2008-08-08 CN CN200880102743.2A patent/CN101827609B/zh active Active
- 2008-08-08 ES ES08782673.1T patent/ES2517872T3/es active Active
- 2008-08-08 SI SI200831344T patent/SI2187964T1/sl unknown
- 2008-08-08 HR HRP20141025AT patent/HRP20141025T1/hr unknown
- 2008-08-08 DK DK08782673.1T patent/DK2187964T3/en active
- 2008-08-08 RS RS20140642A patent/RS53661B1/sr unknown
- 2008-08-08 EP EP12198210.2A patent/EP2572729A3/en not_active Withdrawn
- 2008-08-08 NZ NZ583200A patent/NZ583200A/en unknown
- 2008-08-08 RU RU2010108525/10A patent/RU2473564C2/ru active
- 2008-08-08 ME MEP-2014-642A patent/ME02239B/me unknown
- 2008-08-08 KR KR1020157030908A patent/KR101709495B1/ko active Active
- 2008-08-08 MY MYPI2010000492A patent/MY153781A/en unknown
- 2008-08-08 AU AU2008287037A patent/AU2008287037B2/en active Active
- 2008-08-08 PL PL08782673T patent/PL2187964T3/pl unknown
- 2008-08-08 BR BRPI0815370A patent/BRPI0815370B8/pt active IP Right Grant
- 2008-08-08 EP EP08782673.1A patent/EP2187964B1/en active Active
- 2008-08-08 MY MYPI2012003560A patent/MY161564A/en unknown
- 2008-08-08 ME MEP-2010-24A patent/ME00977B/me unknown
- 2008-08-08 MX MX2010001395A patent/MX2010001395A/es active IP Right Grant
- 2008-08-08 WO PCT/US2008/072561 patent/WO2009023540A1/en not_active Ceased
- 2008-08-08 PT PT87826731T patent/PT2187964E/pt unknown
- 2008-08-08 JP JP2010520319A patent/JP5632744B2/ja active Active
-
2010
- 2010-01-27 IL IL203558A patent/IL203558A/en active IP Right Grant
- 2010-01-29 ZA ZA2010/00725A patent/ZA201000725B/en unknown
- 2010-02-02 NI NI201000021A patent/NI201000021A/es unknown
- 2010-02-05 TN TNP2010000059A patent/TN2010000059A1/fr unknown
- 2010-02-08 DO DO2010000054A patent/DOP2010000054A/es unknown
- 2010-02-10 CO CO10014722A patent/CO6261383A2/es active IP Right Grant
- 2010-02-25 CR CR11298A patent/CR11298A/es unknown
- 2010-03-08 MA MA32679A patent/MA31695B1/fr unknown
- 2010-03-10 EC EC2010010029A patent/ECSP10010029A/es unknown
-
2011
- 2011-06-23 US US13/166,905 patent/US8148107B2/en active Active
-
2012
- 2012-02-28 US US13/406,734 patent/US8613927B2/en active Active
-
2015
- 2015-01-02 CY CY20151100003T patent/CY1116072T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02239B (me) | Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta | |
| JP7488323B2 (ja) | 抗ｌａｇ－３抗体および組成物 | |
| TWI606118B (zh) | 人類類ｔｎｆ配體１ａ（ｔｌ１ａ）之人類抗體 | |
| ES2802241T3 (es) | Uso médico de anticuerpos humanos de alta afinidad dirigidos contra el receptor humano de IL-4 | |
| AU2008338591B8 (en) | Binding molecules to the human OX40 receptor | |
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| RU2010107175A (ru) | Антитела человека к cd20 человека и способ их использования | |
| RU2012107286A (ru) | Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2 | |
| HRP20140108T1 (hr) | Protutijela protiv sklerostina | |
| RU2018100129A (ru) | Способы лечения подагры | |
| JP2012532851A5 (me) | ||
| JP2023155262A (ja) | プレクチン１結合抗体およびその使用 | |
| EP3227334A1 (en) | Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof for use in treating bone associated pain | |
| JP6663910B2 (ja) | 抗ＴＮＦ−α抗体療法を受けた乾癬患者を治療するための方法 | |
| US20160319027A1 (en) | Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof | |
| US20170362327A1 (en) | Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof for use in treating bone associated pain | |
| RU2023126190A (ru) | Человеческие антитела к артемину и способы их применения | |
| RU2021119914A (ru) | Антитела против комплекса angptl3/8 и способы их использования | |
| EA046220B1 (ru) | Анти-lag-3 антитела и их композиции | |
| NZ782617B2 (en) | Antibody molecules to APRIL and uses thereof |